NovaBridge Reports Positive Phase 1b Results for Givastomig in Gastric Cancer with 77% Response Rate
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Should l Buy NBP?
Source: Benzinga
- Clinical Trial Progress: NovaBridge's Phase 1b study evaluating givastomig in combination with nivolumab and mFOLFOX6 shows an overall response rate of 77% for the 8 mg/kg cohort and 73% for the 12 mg/kg cohort, indicating significant potential for this therapy in treating HER2-negative metastatic gastric cancer.
- Survival Data: The median progression-free survival (PFS) reached 16.9 months in the 8 mg/kg group, while PFS data for the 12 mg/kg group remains immature, highlighting the promising outlook of this treatment in extending patient survival.
- Safety Analysis: The combination therapy was generally well tolerated, with a safety profile comparable to standard care, and immune-related gastritis was observed to correlate with improved clinical outcomes, suggesting both safety and efficacy warrant attention.
- Future Research Plans: NovaBridge plans to initiate a global randomized Phase 2 study in Q1 2026 to evaluate both doses against standard care, with detailed Phase 1b dose expansion data expected to be presented at a medical conference later in 2026, further advancing the clinical development pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBP
Wall Street analysts forecast NBP stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.700
Low
7.00
Averages
8.00
High
9.00
Current: 2.700
Low
7.00
Averages
8.00
High
9.00
About NBP
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
I-Mab Biopharma Reports FY GAAP EPS
- Earnings Report: I-Mab Biopharma reported a FY GAAP EPS of -$0.48, indicating challenges in profitability that may affect investor confidence and stock performance.
- Cash Position: As of December 31, 2025, the company had $210.8 million in cash, cash equivalents, and short-term investments, with the current cash position expected to support operations through 2028, ensuring financial stability in the coming years.
- Clinical Data Discussion: NovaBridge Biosciences discussed Phase 2a clinical data and development plans for VIS-101 in wet age-related macular degeneration, highlighting ongoing R&D investments that could lay the groundwork for future product launches.
- Market Reaction Outlook: The financial data and clinical advancements from I-Mab Biopharma may influence market expectations regarding its future growth potential, prompting investors to monitor subsequent R&D outcomes and financial improvements.
See More
NovaBridge Successfully Transforms into a Global Biotech Platform
- Clinical Trial Progress: NovaBridge's givastomig demonstrates a 75% objective response rate in gastric cancer trials, with a median progression-free survival of 16.9 months among 52 evaluable patients, indicating strong market competitiveness.
- FDA Accelerated Approval Potential: Givastomig confirmed potential eligibility for the Accelerated Approval pathway at an FDA Type B meeting, with a registrational Phase 3 trial expected to initiate in Q4 2026, further advancing its commercialization prospects.
- Strong Financial Position: As of December 31, 2025, NovaBridge reported $210.8 million in cash, expected to support operations through 2028, showcasing the company's robust financial capacity for R&D and market expansion.
- Executive Team Expansion: NovaBridge has expanded its Board of Directors and executive team by appointing several industry experts to drive growth, reflecting its strategic positioning in the global biotech sector and confidence in future developments.
See More
NOVABRIDGE ANNOUNCES 2025 FULL YEAR FINANCIAL RESULTS AND BUSINESS UPDATE
Financial Results: Novabridge reports its full-year financial results for 2025, highlighting key performance metrics and overall financial health.
Business Update: The report provides a comprehensive business update, detailing recent developments and strategic initiatives undertaken by the company.
See More
NovaBridge Secures FDA Confirmation for Accelerated Approval Potential of Givastomig
- FDA Approval Pathway Confirmation: NovaBridge's meeting with the FDA confirmed the potential for accelerated approval of givastomig in 1L Her2-, CLDN 18.2+, PD-L1+ gastric cancer patients, marking a significant milestone in the company's innovative drug development.
- Registration Trial Plans: The company plans to initiate a registrational Phase 3 trial in Q4 2026, combining immunochemotherapy with a primary endpoint of objective response rate (ORR), which will provide critical data support for accelerated approval.
- Clinical Trial Results: In the Phase 1b trial, givastomig demonstrated a 75% ORR, showing good responses across varying PD-L1 and CLDN 18.2 expression levels, indicating its potential in gastric cancer treatment.
- Broad Market Prospects: As the first bispecific antibody targeting CLDN 18.2, givastomig is poised to become a best-in-class option for gastric cancer treatment, further solidifying NovaBridge's market position in the biopharmaceutical sector.
See More
NovaBridge Biosciences Reports Positive Phase 2a Results for VIS-101
- Clinical Trial Results: NovaBridge Biosciences' VIS-101 demonstrated significant efficacy in the Phase 2a trial for wet age-related macular degeneration (AMD), with both 3 mg and 6 mg cohorts showing improvements of over 10 ETDRS letters in Best Corrected Visual Acuity (BVCA) and reductions in central subfield thickness (CST) by 100-150 mm, indicating strong therapeutic potential.
- Patient Safety: The study enrolled 38 patients in China, revealing a favorable safety profile for VIS-101 with no dose-limiting toxicity, which positions the drug as a potential best-in-class treatment option and enhances market confidence in its prospects.
- Future Research Plans: The company plans to initiate a dose-determining Phase 2b study in the second half of 2026, followed by a global Phase 3 program in 2027, which will support the market introduction and clinical application of VIS-101, potentially driving future growth for the company.
- Market Performance Analysis: Despite a 23.08% decline in NovaBridge Biosciences' stock over the past 12 months, the current stock price is 14.2% above its 20-day simple moving average (SMA), indicating short-term strength; combined with a neutral RSI and bullish MACD, this suggests optimistic market sentiment regarding the company's future outlook.
See More
Ooma Inc Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Ooma Inc reported Q4 earnings of $0.34 per share, surpassing analyst expectations of $0.30, indicating strong profitability growth and boosting market confidence in its future performance.
- Sales Growth: The company achieved quarterly sales of $74.584 million, exceeding the analyst consensus of $72.549 million, reflecting Ooma's solid performance in market demand and product sales, which helps increase its market share.
- Stock Surge: Ooma's shares jumped 11.3% to $14.46 during Thursday's session, reflecting a positive investor reaction to the company's financial performance, potentially attracting more investor interest.
- Optimistic Outlook: Ooma issued FY27 adjusted EPS guidance above market expectations, further enhancing investor confidence in the company's long-term growth potential.
See More
I-Mab Biopharma Reports FY GAAP EPS
- Earnings Report: I-Mab Biopharma reported a FY GAAP EPS of -$0.48, indicating challenges in profitability that may affect investor confidence and stock performance.
- Cash Position: As of December 31, 2025, the company had $210.8 million in cash, cash equivalents, and short-term investments, with the current cash position expected to support operations through 2028, ensuring financial stability in the coming years.
- Clinical Data Discussion: NovaBridge Biosciences discussed Phase 2a clinical data and development plans for VIS-101 in wet age-related macular degeneration, highlighting ongoing R&D investments that could lay the groundwork for future product launches.
- Market Reaction Outlook: The financial data and clinical advancements from I-Mab Biopharma may influence market expectations regarding its future growth potential, prompting investors to monitor subsequent R&D outcomes and financial improvements.
See More
NovaBridge Successfully Transforms into a Global Biotech Platform
- Clinical Trial Progress: NovaBridge's givastomig demonstrates a 75% objective response rate in gastric cancer trials, with a median progression-free survival of 16.9 months among 52 evaluable patients, indicating strong market competitiveness.
- FDA Accelerated Approval Potential: Givastomig confirmed potential eligibility for the Accelerated Approval pathway at an FDA Type B meeting, with a registrational Phase 3 trial expected to initiate in Q4 2026, further advancing its commercialization prospects.
- Strong Financial Position: As of December 31, 2025, NovaBridge reported $210.8 million in cash, expected to support operations through 2028, showcasing the company's robust financial capacity for R&D and market expansion.
- Executive Team Expansion: NovaBridge has expanded its Board of Directors and executive team by appointing several industry experts to drive growth, reflecting its strategic positioning in the global biotech sector and confidence in future developments.
See More
NOVABRIDGE ANNOUNCES 2025 FULL YEAR FINANCIAL RESULTS AND BUSINESS UPDATE
Financial Results: Novabridge reports its full-year financial results for 2025, highlighting key performance metrics and overall financial health.
Business Update: The report provides a comprehensive business update, detailing recent developments and strategic initiatives undertaken by the company.
See More
NovaBridge Secures FDA Confirmation for Accelerated Approval Potential of Givastomig
- FDA Approval Pathway Confirmation: NovaBridge's meeting with the FDA confirmed the potential for accelerated approval of givastomig in 1L Her2-, CLDN 18.2+, PD-L1+ gastric cancer patients, marking a significant milestone in the company's innovative drug development.
- Registration Trial Plans: The company plans to initiate a registrational Phase 3 trial in Q4 2026, combining immunochemotherapy with a primary endpoint of objective response rate (ORR), which will provide critical data support for accelerated approval.
- Clinical Trial Results: In the Phase 1b trial, givastomig demonstrated a 75% ORR, showing good responses across varying PD-L1 and CLDN 18.2 expression levels, indicating its potential in gastric cancer treatment.
- Broad Market Prospects: As the first bispecific antibody targeting CLDN 18.2, givastomig is poised to become a best-in-class option for gastric cancer treatment, further solidifying NovaBridge's market position in the biopharmaceutical sector.
See More
NovaBridge Biosciences Reports Positive Phase 2a Results for VIS-101
- Clinical Trial Results: NovaBridge Biosciences' VIS-101 demonstrated significant efficacy in the Phase 2a trial for wet age-related macular degeneration (AMD), with both 3 mg and 6 mg cohorts showing improvements of over 10 ETDRS letters in Best Corrected Visual Acuity (BVCA) and reductions in central subfield thickness (CST) by 100-150 mm, indicating strong therapeutic potential.
- Patient Safety: The study enrolled 38 patients in China, revealing a favorable safety profile for VIS-101 with no dose-limiting toxicity, which positions the drug as a potential best-in-class treatment option and enhances market confidence in its prospects.
- Future Research Plans: The company plans to initiate a dose-determining Phase 2b study in the second half of 2026, followed by a global Phase 3 program in 2027, which will support the market introduction and clinical application of VIS-101, potentially driving future growth for the company.
- Market Performance Analysis: Despite a 23.08% decline in NovaBridge Biosciences' stock over the past 12 months, the current stock price is 14.2% above its 20-day simple moving average (SMA), indicating short-term strength; combined with a neutral RSI and bullish MACD, this suggests optimistic market sentiment regarding the company's future outlook.
See More
Ooma Inc Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Ooma Inc reported Q4 earnings of $0.34 per share, surpassing analyst expectations of $0.30, indicating strong profitability growth and boosting market confidence in its future performance.
- Sales Growth: The company achieved quarterly sales of $74.584 million, exceeding the analyst consensus of $72.549 million, reflecting Ooma's solid performance in market demand and product sales, which helps increase its market share.
- Stock Surge: Ooma's shares jumped 11.3% to $14.46 during Thursday's session, reflecting a positive investor reaction to the company's financial performance, potentially attracting more investor interest.
- Optimistic Outlook: Ooma issued FY27 adjusted EPS guidance above market expectations, further enhancing investor confidence in the company's long-term growth potential.
See More
